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INTRODUCTION
Radiofrequency catheter ablation (RFCA) has become an im-
portant rhythm control therapy in the management of anti-ar-
rhythmic drug-resistant atrial fibrillation (AF).1,2 However, the 
risk of procedure-related thromboembolic events exists at the 
time of catheter ablation, and the embolic risk is reportedly in 
the range 0.4–2.0%.3-5 Most strokes occur within 24 hours of 
the procedure.5 Therefore, an optimal peri-procedural antico-
agulation is required, although its specific details have not 
been determined. Most patients with AF take oral anticoagu-
lants. Anticoagulation guidelines that pertain to cardioversion 
of AF have been proposed for patients who present for AF ab-
lation at the time of the procedure.6 Therefore, if the patient 
has been in AF for 48 hours or longer or for an unknown dura-
tion, most experts prescribe 3 weeks of effective oral anticoag-
ulation prior to the RFCA. Since there are no studies compar-
ing the use of heparin with no heparin use during RFCA, all 
patients receive intra-procedural heparin regardless of antico-
agulation status or anticoagulant use. After a successful proce-
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dure, oral anticoagulants are usually restarted after hemosta-
sis is achieved and then continued for at least 2–3 months, 
even in patients with a low CHA2DS2-VASc score.7 Several stud-
ies have recently examined the peri-procedural management 
of novel oral anticoagulants (NOACs) for patients who are 
scheduled to undergo RFCA.8-12 The advantages of NOACs as 
peri-procedural anticoagulants include a rapid onset of action 
with shorter time required to achieve therapeutic anticoagula-
tion and no concern for a sub- or supra-therapeutic interna-
tional normalized ratio (INR) on the day of the procedure. In 
contrast, although there is a consensus that pre-procedural 
uninterrupted warfarin is safe and effective for preventing pro-
cedure-related thromboembolism,13 termination of NOACs for 
24–48 hours before the procedure has been recommended by 
the European Heart Rhythm Association (EHRA) practical 
guide.14 Therefore, we hypothesized that NOACs are non-infe-
rior to continuous warfarin in the peri-procedural period of AF 
catheter ablation, despite the transient blanking period. The 
purpose of our study was to compare the use of NOACs and 
uninterrupted warfarin in the peri-procedural period for AF 
catheter ablation in terms of safety, efficacy, and intra-proce-
dural heparin requirement.
MATERIALS AND METHODS
Study design
The study protocol adhered to the principles of the Declara-
tion of Helsinki and was approved by the Institutional Review 
Board of Yonsei University Health System. All patients provid-
ed written informed consent. Among 632 consecutive patients 
in the Yonsei AF ablation cohort between September 2012 
and October 2014, 141 patients taking peri-procedural NOACs 
(72% men; 58±11 years old; 71% with paroxysmal AF) were 
initially compared to 491 patients taking uninterrupted warfa-
rin before AF ablation. We then conducted propensity score 
matching between the continuous warfarin group and the 
NOAC group. A total of 141 patients in the NOAC group and 
281 age-, sex-, AF type-, and history of stroke-matched patients 
in the warfarin group were compared. All patients had anti-ar-
rhythmic drug-refractory AF and underwent RFCA. All patients 
received warfarin or NOAC as oral anticoagulants prior to the 
procedure for 3 or more weeks. All patients, including those 
with effective pre-procedural oral anticoagulation, underwent 
transesophageal echocardiography (TEE) prior to RFCA. The 
choice of oral anticoagulant was decided based on the prefer-
ence of the cardiologists or primary care physicians who treat-
ed the patients before the procedure. Among the 141 patients 
in the NOAC group, 11 were switched from warfarin after the 
referral because of an unstable INR. 
We assessed each patient’s heparin requirement and acti-
vated clotting time (ACT) during the procedure, and thrombo-
embolic and bleeding complications during 30 days post-AF 
ablation. Thromboembolic complication was defined as 
stroke, transient ischemic attack (TIA), or systemic embolism. 
Bleeding complications were classified as major or minor 
bleeding. Major bleeding was defined as pericardial tampon-
ade or bleeding including a hematoma requiring a blood trans-
fusion or a decreased level of hemoglobin ≥4.0 g/dL without 
an overt source.15 Minor bleeding was defined as bleeding with 
a decreased hemoglobin level at 3.0–4.0 g/dL without an overt 
source, groin hematoma, or pericardial effusion without tam-
ponade. Hematoma was defined as any significant palpable 
mass associated with purpura at skin level.16 We also evaluated 
vascular complications (any identified pseudoaneurysm or 
arteriovenous fistula) that required re-hospitalization or lon-
ger hospitalization. We compared the NOAC and warfarin 
groups for 1) duration of pre-procedural anticoagulation, 2) in-
tra-procedural heparin requirement, and 3) intra-procedural 
ACT, and 4) complication of thromboembolism, and 5) bleed-
ing during the 30-day post-RFCA period.
Anticoagulation 
We continued anticoagulation therapy for patients presenting 
for RFCA who were taking warfarin. The target therapeutic INR 
was 2.0–3.0. The INR was checked on a monthly basis before 
the procedure and on the same day as the procedure. Warfarin 
was continued at a maintenance dose (INR 2.0–3.0) after the 
procedure. For patients taking a NOAC (dabigatran, rivaroxa-
ban, or apixaban) who presented for RFCA, we discontinued 
two doses of dabigatran and apixaban and single doses of riva-
roxaban before procedure, and restarted NOAC on the day of 
the procedure after confirming hemostasis following sheath 
removal. All patients received intra-procedural anticoagula-
tion with intravenous heparin. Initial bolus doses of unfrac-
tionated heparin (100 IU/kg) were administered before trans-
septal puncture. The ACT was monitored every 10–30 min 
throughout the procedures and adjusted as needed with peri-
odic heparin boluses. The intensity of heparinization main-
tained was at an ACT of 350–400 s during the procedure. Oral 
anticoagulation was then continued for at least 3 months after 
the procedure in all patients. 
Radiofrequency catheter ablation 
Details regarding electrophysiological mapping and RFCA 
technique and strategy were described in previous studies.17,18 
In brief, an open irrigation 3.5-mm-tip deflectable catheter 
(Celsius, Johnson & Johnson Inc.; Diamond Bar, CA, USA; 
Coolflex, St. Jude Medical Inc., Minnetonka, MN, USA; 30–35 
W; 47°C) was used for RFCA (Stockert generator, Biosense 
Webster Inc., Diamond Bar, CA, USA). Circumferential pul-
monary vein isolation and bi-directional block of the cavotri-
cuspid isthmus ablation were performed in all patients. For 
patients with persistent AF, we added a roof line, posterior in-
ferior line, and anterior line as a standard lesion set. Addition-
al ablation of the superior vena cava or non-pulmonary vein 
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foci or after complex fractionated electrography was deter-
mined by the operator. 
Follow-up after ablation
All patients were followed up after the procedure with anti-ar-
rhythmic drugs discontinued. All patients were monitored 
with continuous electrocardiography overnight and dis-
charged the day after the procedure. All patients were sched-
uled for outpatient clinic follow-ups and rhythm follow-ups 
according to the 2012 Heart Rhythm Society/EHRA/European 
Cardiac Arrhythmia Society Expert Consensus Statement guide-
lines.6 In this study, we compared the efficacy and safety of 
NOACs and warfarin within 1 month of the AF ablation.
Statistical analysis
The baseline characteristics between the NOAC and warfarin 
groups were compared. Continuous variables are reported as 
mean±standard deviation (SD) and analyzed using the Stu-
dent t-test. Categorical variables were reported as counts and 
proportions and analyzed using Pearson chi-square test or 
Fisher exact test as appropriate. Propensity score matching 
was used to reduce the selection bias associated with the oral 
anticoagulant treatment and potential confounding bias in an 
observational study and to adjust for the differences in the pa-
tients’ characteristics.19 At the initial comparison, AF type and 
history of stroke/TIA were statistically different between 
NOAC group and warfarin group. Therefore, we chose those 2 
variables, age, and sex as references for propensity score match-
ing. The following variables were considered each time a pa-
tient from the NOAC group was matched to a maximum of two 
patients from the warfarin group. A matching caliper of 0.05 
SD of the logit of the estimated propensity score was enforced 
using R package, including Matchit, RI tools, and CEM.19 The 
SPSS statistical package version 20.0 (SPSS Inc., Chicago, IL, 
USA) was used to perform all of the statistical evaluations. p 
values ≤0.05 were considered statistically significant. 
RESULTS
Baseline characteristics 
The patient population comprised 141 patients in the NOAC 
group and 491 patients in the uninterrupted warfarin group. 
We selected 281 patients in the warfarin group after age-, sex-, 
AF type-, and history of stroke-matching and compared them 
with the 141 patients in the NOAC group. Patients in the NOAC 
group were prescribed dabigatran (n=99; 70.2%), rivaroxaban 
(n=18; 12.8%), or apixaban (n=24; 17.0%). Table 1 compares 
the baseline characteristics of the study population according 
to oral anticoagulant. Before propensity score matching, NO-
ACs were more likely to be prescribed for patients with parox-
ysmal AF (p=0.004) and those without a history of stroke/TIA 
(p=0.034). After age-, sex-, AF type-, and history of stroke-
matching, the duration of pre-procedural anticoagulation was 
significantly shorter in the NOAC group than in the warfarin 
group (76.3±110.7 days vs. 274.7±582.7 days, p<0.001). None 
Table 1. Baseline Characteristics of the Study Population
Total population Propensity score-matched population
Overall (n=632) NOACs (n=141) Warfarin (n=491) p value NOACs (n=141) Warfarin (n=281) p value
Age 58.4±11.0 58.5±12.7 58.4±10.9 0.919 58.5±11.7 58.1±10.9 0.706
Sex, male 454 (71.8) 101 (71.6) 353 (71.9) 0.951 101 (71.6) 210 (74.7) 0.495
Body mass index, kg/m2 24.9±2.9 24.5±2.9 25.0±3.0 0.131 24.5±2.9 24.8±3.0 0.378
Medical history 
Diabetes 74 (11.7) 14 (9.9) 60 (12.2) 0.456 14 (9.9) 34 (12.1) 0.508
Hypertension 291 (46.0) 57 (40.4) 234 (47.7) 0.129 57 (40.4) 125 (44.5) 0.427
Heart failure 83 (13.0) 14 (9.9) 68 (13.8) 0.222 14 (9.9) 29 (10.3) 0.900
History of stroke/TIA 83 (13.1) 11 (7.8) 72 (14.7) 0.034 11 (7.8) 20 (7.1) 0.799
Paroxysmal AF 449 (71.0) 114 (80.9) 335 (68.2) 0.004 114 (80.9) 225 (80.1) 0.849
Score system 
CHA2DS2-VASc score 1.8±1.6 1.7±1.7 1.8±1.6 0.493 1.7±1.7 1.5±1.4 0.376
HAS-BLED score 1.3±1.4 1.4±1.6 1.3±1.4 0.560 1.4±1.6 1.2±1.3 0.175
Duration of anticoagulation, days 238.6±493.0 76.3±110.7 284.3±546.6 <0.001 76.3±110.7 274.7±582.7 <0.001
Echocardiographic value
LV ejection fraction, % 62.6±9.0 63.5±8.8 62.4±8.9 0.182 63.5±8.8 63.0±8.7 0.532
LAVI, mL/m2 35.4±13.0 34.2±13.5 35.8±12.8 0.180 34.2±13.5 33.9±11.8 0.865
AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes mellitus, and prior ischemic Stroke, transient ischemic 
attack or thromboembolism (doubled), Vascular disease, Age 65–74, Sex category (female); HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, 
Bleeding tendency or predisposition, Labile INR, Elderly (e.g., >65), Drugs (e.g., aspirin, clopidogrel or non-steroidal antiinflammatory drug), Alcohol abuse; LAVI, 
left atrial volume index; LV, left ventricle; NOACs, novel oral anticoagulants; TIA, transient ischemic attack.
Numbers in parenthesis are in percentages.
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of the other variables significantly differed between the two 
groups. 
Intra-procedural characteristics
There was no significant difference in total procedure (181.8± 
47.9 min vs. 177.2±52.0 min, p=0.387) and total ablation times 
(4364.5±1560.1 s vs. 4353.4±1563.6 s, p=0.945) between the 
NOAC and warfarin groups. During the procedure, the mean 
ACT differed significantly between the NOAC and warfarin 
groups (350.0±25.0 s vs. 367.4±42.9 s, p<0.001) (Fig. 1A). The 
total dose of unfractionated heparin to maintain a therapeutic 
ACT during RFCA was significantly higher in the NOAC group 
than in the warfarin group (18068.3±6844.4 IU vs. 11890.3± 
5808.1 IU, p<0.001) (Fig. 1B).
Complications 
The overall rate of peri-procedural complications, including 
minor bleeding, was 11.1% (70/632) (Table 2). Two thrombo-
embolic (0.3%), 44 bleeding (7.0%), and 17 vascular complica-
tions (2.7%) occurred during the 30-day follow-up period. Al-
though stroke-related events tended to occur more often in the 
NOAC group (1.4% vs. 0%, p=0.049), bleeding (4.3% vs. 7.7%, 
p=0.152) and vascular complications (1.4% vs. 3.1%, p=0.386) 
did not differ between the groups. The overall complication 
rate was not significantly different after age-, sex-, AF type-, 
and history of stroke-matching. There were two cases of post-
procedural stroke in the NOAC group (Table 3). One patient 
complained of vomiting and headache immediately after the 
procedure, while another manifested diplopia 10 hours after 
RFCA. Both patients showed small acute infarctions docu-
mented by brain magnetic resonance imaging (Fig. 2). These 
Fig. 1. Comparison of mean ACT (A) and total heparin dosage (B) between patients in the NOAC and warfarin groups during the procedure. ACT, activated 
clotting time; NOAC, novel oral anticoagulant.
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Table 2. Procedural Complications of the Study Population
Total population Propensity score-matched population
Overall
(n=632)
NOACs
(n=141)
Warfarin
(n=491)
p value
NOACs
(n=141)
Warfarin
(n=281)
p value
Total complications 70 (11.1) 12 (8.5) 58 (11.8) 0.271 12 (8.5) 27 (9.6) 0.713
Thromboembolic complications 2 (0.3) 2 (1.4) 0 (0) 0.049 2 (1.4) 0 (0) 0.111
Stroke 2 (0.3) 2 (1.4) 0 (0) 0.049 2 (1.4) 0 (0) 0.111
Bleeding complications 44 (7.0) 6 (4.3) 38 (7.7) 0.152 8 (5.7) 21 (7.5) 0.491
Major 10 (2.0) 0 (0) 10 (2.0) 0.128 0 (0) 4 (1.4) 0.306
Periprocedural cardiac tamponade 7 (1.1) 0 (0) 7 (1.4) 0.358 0 (0) 3 (1.1) 0.554
Hb decrease ≥4 g/dL without overt source 3 (0.5) 0 (0) 3 (0.6) 1.000 0 (0) 1 (0.4) 1.000
Minor 34 (5.4) 6 (4.3) 28 (5.7) 0.502 6 (4.3) 15 (5.3) 1.000
3 g/dL ≤Hb decrease <4 g/dL without overt source 5 (0.8) 2 (1.4) 3 (0.6) 0.310 2 (1.4) 0 (0) 0.111
Groin hematoma 28 (4.4) 4 (2.8) 24 (4.9) 0.297 4 (2.8) 14 (5.0) 0.304
Pericardial effusion without tamponade 1 (0.2) 0 (0) 1 (0.2) 1.000 0 (0) 1 (0.4) 1.000
Vascular complications 17 (2.7) 2 (1.4) 15 (3.1) 0.386 2 (1.4) 6 (2.1) 0.724
Pseudoaneurysm 11 (1.7) 1 (0.7) 10 (2.0) 0.471 1 (0.7) 3 (1.1) 1.000
AV fistula 6 (0.9) 1 (0.7) 5 (1.0) 1.000 1 (0.7) 3 (1.1) 1.000
AV, arteriovenous; Hb, hemoglobin; NOACs, novel oral anticoagulants.
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patients had a CHA2DS2-VASc score ≤1 and paroxysmal AF. 
Both patients recovered without neurological sequelae after 
medical therapy.
DISCUSSION
In the present study, we explored the difference between the 
use of NOACs and uninterrupted warfarin in the peri-proce-
dural period in patients with AF who underwent catheter ab-
lation. In this retrospective observational study, pre-procedur-
al anticoagulation duration was shorter and intra-procedural 
heparin requirement was higher with NOAC than with unin-
terrupted warfarin in AF ablation. Although the incidences of 
peri-procedural thromboembolism and bleeding did not dif-
fer, there were two cases of minor stroke in the NOAC group 
with pre-procedural blanking of the anticoagulation.
Comparisons of NOAC and warfarin in patients with 
non-valvular AF
Options for anticoagulation have expanded steadily over the 
past few decades, providing a greater number of agents for 
preventing and managing thromboembolic disease. In partic-
ular, anticoagulation with NOACs have led to similar or lower 
rates of both ischemic stroke and major bleeding, compared 
to warfarin, in patients with non-valvular AF in large random-
ized trials.20 These results support the broad concept that NO-
ACs are preferable to warfarin in many cases. For example, 
the use of peri-ablation anticoagulation with NOACs has been 
rapidly expanding worldwide. The majority of similar studies 
has reported non-inferiority or even superiority of NOACs in 
terms of thromboembolism and bleeding complications.21-25 
As with most studies, our study showed no difference in the 
peri-procedural incidences of thromboembolism and bleed-
ing during AF ablation in the NOAC and warfarin groups. 
Fig. 2. Diffusion-weighted magnetic resonance imaging of two patients after atrial fibrillation catheter ablation displaying smaller foci of restricted diffu-
sion in (A) the right frontal lobe (arrow) and (B) the left dorsal pons (arrow).
A B
Table 3. Characteristics of Patients with Thromboembolic Events 30 Days after Arterial Fibrillation Ablation
No.
Sex/ 
age
Event  
characteristics
Hours after 
ablation
AF  
classification
CHADS2/
CHA2DS2-VASc
Anticoagulation  
type and duration
Ablation 
time (sec)
Hospital  
duration 
(days)
Management
Neurological 
sequelae
1 M/40
Stroke,
right frontal lobe
0 Paroxysmal AF 0/0
NOAC, 26 days
(apixaban 5 mg BID)
3879 3 Medical None
2 M/56
Stroke, left 
dorsal pons
10 Paroxysmal AF 1/1
NOAC, 40 days
(dabigatran 150 mg BID)
4244 6 Medical None
M, male; AF, atrial fibrillation; CHADS2, Congestive heart failure, Hypertension, Age ≥75, Diabetes mellitus, and prior Stroke or transient ischemic attack (dou-
bled); CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes mellitus, and prior ischemic Stroke, transient ischemic attack or 
thromboembolism (doubled), Vascular disease, Age 65–74, Sex category (female); HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding ten-
dency or predisposition, Labile INR, Elderly (e.g., >65), Drugs (e.g., aspirin, clopidogrel or non-steroidal antiinflammatory drug), Alcohol abuse; NOACs, novel oral 
anticoagulants.
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Advantages and disadvantages in NOAC use 
in the peri-procedural period
Anticoagulant use must be balanced to minimize thromboem-
bolic and bleeding risks, as well as complications and side ef-
fects, in patients undergoing AF catheter ablation.26 Compared 
to uninterrupted warfarin, NOAC has several advantages for 
use in the peri-procedural period of RFCA for AF in terms of 
convenience (no requirement for routine testing of INR, no 
need for frequent dose adjustment, and rapid onset of action) 
and less susceptibility to dietary and drug interactions. Since 
saturation of warfarin and maintaining an optimal INR is dif-
ficult, especially in outpatient clinics,27,28 the shorter duration 
of pre-procedural anticoagulation in the NOAC group versus 
the warfarin group reflects the convenience of NOAC use. In 
contrast, NOACs have the following disadvantages: 1) lack of 
an approved antidote/reversing agent; 2) limited data for effi-
cacy and safety (in patients with chronic kidney disease and 
long-term adverse effects); 3) lack of easily available monitor-
ing of blood levels and compliance; 4) higher cost; and 5) the 
required pre-procedural blanking period immediate before 
AF ablation. 
The EHRA Practical Guide suggests that discontinuation 
and restarting of anticoagulation should be individualized to 
consider both patient characteristics (kidney function, age, his-
tory of bleeding complications, concomitant medication) and 
procedural factors according to the types of NOACs used.6 
However, in many studies on the use of NOACs in ablation, 
the time for stopping anticoagulation has differed. Some stud-
ies stopped anticoagulation on the night before the proce-
dure,21,29 while others have uninterrupted anticoagulation.11,12,24 
Although there was no statistical difference in thromboembol-
ic or hemorrhagic complications between the NOAC and 
warfarin groups in this study, there were two cases of minor 
stroke in the NOAC group. In non-valvular AF, high CHA2DS2-
VASc scores reportedly reflect a high risk of stroke;30 however, 
both patients in this study had low CHA2DS2-VASc scores. 
Also, we previously reported that routine pre-procedural TEE 
is not mandatory for stroke prevention evaluation in patients 
with AF on warfarin;31 however, it is not clear whether the 
same strategy is acceptable for patients who are taking NOACs. 
Cappato, et al.32 recently reported that uninterrupted oral riva-
roxaban is feasible and event rates were similar to those for 
uninterrupted warfarin. Therefore, further prospective ran-
domized studies are needed to identify for optimal anticoagu-
lation schedules with other NOACs at the periprocedural pe-
riod, instead of old EHRA practice guidelines14 with limited 
evidence. 
Effects of NOACs on ACT
Heparin plays some role in the intrinsic coagulation pathways 
and manifests anticoagulation effects. In contrast, warfarin af-
fects not only the intrinsic coagulation pathways, but also co-
agulation factor IX in the intrinsic pathways and coagulation 
factors X and II in the common pathways.33 NOACs clearly af-
fect the common pathways, although each drug targets differ-
ent coagulation factors. The target coagulation factors are fac-
tor II for dabigatran and factor Xa for rivaroxaban and apixaban. 
We previously reported on the reduced intra-procedural hep-
arin requirement with continuous warfarin strategy, compared 
to switching to heparin group.13 Saturated warfarin or NOACs 
increased the ACT and reduced the heparin requirement dur-
ing the procedure, and a significantly higher heparin require-
ment in the NOAC group than in the uninterrupted warfarin 
group was related to skipping anticoagulation in both this 
study and other studies.21,22,24 
Limitations
Since this was a single-center cohort study that included a se-
lective group of patients referred for AF catheter ablation, its 
results cannot be generalized. Given that most of the previous 
investigations exploring AF were performed in Caucasian 
populations, the findings from this study in an Asian popula-
tion are valuable. This study was non-randomized, and the an-
ticoagulant used in each patient was based on the clinician’s 
preference. This selection bias is visible in the patients’ baseline 
characteristics. To minimize the selection bias, we conducted 
age-, sex-, AF type-, and history of stroke-matching based on 
propensity score. We did not analyze the results according to 
the different NOACs. Although we tried to follow EHRA prac-
tice guidelines,14 it was not easy to enforce 24 hours of absti-
nence before the procedure. Therefore, we skipped two doses 
of dibigatran or apixaban and a single dose of rivaroxaban. 
Further double-blind studies are needed for in-depth com-
parisons of NOACs according to each subset of medication, as 
are studies with a larger number of patients. 
Conclusion
The pre-procedural anticoagulation duration was shorter in 
the NOAC group than in the warfarin group in patients who 
underwent AF catheter ablation. Although the intra-proce-
dural heparin requirement was higher and ACT was lower in 
the NOAC group, there were no differences in peri-procedural 
thromboembolism and bleeding complications. However, we 
must pay special attention to the anticoagulation blanking pe-
riod and the potential poor compliance of patients treated 
with NOACs immediate before AF catheter ablation.
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